Document is current
Any future updates will be listed below
-
Authors
Zangari, Joséphine
Stehling, Oliver https://orcid.org/0000-0002-4737-0768
Freibert, Sven A.
Bhattacharya, Kaushik
Rouaud, Florian
Serre-Beinier, Veronique https://orcid.org/0000-0002-6016-1645
Maundrell, Kinsey
Montessuit, Sylvie
Ferre, Sabrina Myriam https://orcid.org/0000-0002-1379-3025
Vartholomaiou, Evangelia https://orcid.org/0000-0002-8664-9999
Schulz, Vinzent
Zuhra, Karim https://orcid.org/0000-0003-0186-1817
González-Ruiz, Víctor https://orcid.org/0000-0001-7204-2363
Hanschke, Sahra
Tsukamoto, Takashi https://orcid.org/0000-0002-0216-7520
Cerezo, Michaël https://orcid.org/0000-0002-3687-2009
Szabo, Csaba https://orcid.org/0000-0003-3110-4235
Rudaz, Serge
Boniecki, Michal T. https://orcid.org/0000-0002-0854-0891
Cygler, Miroslaw https://orcid.org/0000-0003-4579-1881
Lill, Roland https://orcid.org/0000-0002-8345-6518
Martinou, Jean-Claude https://orcid.org/0000-0002-9847-2051
-
Funding
Funding for this research was provided by:
Oncosuisse (KFS-4434-02-2018)
Fondation Ernst et Lucie Schmidheiny
Deutsche Forschungsgemeinschaft (Koselleck grant LI 415/6 and SPP 1927; LI 415/7)
- License Information
-
More Information
Article History
Received: 19 March 2025
Accepted: 23 June 2025
First Online: 12 August 2025
Competing interests
: J.Z. and J.-C.M. filed a patent on the effects of d-Cys in cancer. Patent applicant: Université de Genève. Names of inventors: J.-C.M. and J.Z. Application numbers: EP 21 769 366.2 and US 18/022,824. Status of applications: pending. The patent describes the effects of d-Cys on cell proliferation in vitro and the potential of d-Cys as a therapy for tumours expressing xCT. J.-C.M. serves as an unpaid member of the scientific advisory board of MPC Therapeutics (Geneva, Switzerland). The other authors declare no competing interests.
